Table 2 Patient characteristics

From: Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

Characteristic

N

Entered/evaluable

15/15

Male/female

10/5

Median age (range)

59 (33–71)

ECOG a performance status

 

 0

1

 1

13

 2

1

Primary tumour site

 

 Lung

5

 Mesothelioma

5

 Stomach

1

 Oesophagogastric junction

1

 Prostate

1

 Unknown primary

1

 Cervix

1

Previous chemotherapy regimens

 

 0

0

 1

11

 2 or more

4

Prior platinum

14

Previous radiotherapy

11

Other treatment (vaccines, etc.)

2

  1. aEastern Cancer Oncology Group.